ArticleMicrobiology spectrum2022
Baicalein Acts against Candida albicans by Targeting Eno1 and Inhibiting Glycolysis.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Generation of antifungals to combat drug resistance using language models and diffusion models.Journal of advanced research · 2026Article
- Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy.Cell death & disease · 2026Article
- Review
- The antibacterial activity, action mechanisms and prospects of Baicalein as an antibacterial adjuvant.World journal of microbiology & biotechnology · 2025Review
- Galactose Inhibits the Translation of Erg1 that Enhances the Antifungal Activities of Azoles AgainstAntibiotics (Basel, Switzerland) · 2025Article
- ENO1 fromBiomolecules · 2025Article
- Article
- Virtual screening assisted identification of a phytocompound as potent inhibitor against Candida lusitaniae; an in-silico study.BMC infectious diseases · 2025Article
- Baicalein combined with azoles against fungiFrontiers in microbiology · 2025Article
- Baicalein as a potent antifungal agent againstFrontiers in microbiology · 2025Article
- Impact of Enolase in Allergic Disease.Current allergy and asthma reports · 2024Review
- The Preliminary Analysis of Flavonoids in the Petals ofInternational journal of molecular sciences · 2024Article
- Halofantrine Hydrochloride Acts as an Antioxidant Ability Inhibitor That Enhances Oxidative Stress Damage toAntioxidants (Basel, Switzerland) · 2024Article
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- Molecular cloning, expression, and purification, along withFrontiers in fungal biology · 2024Article
- Unexpected Inhibitory Effect of Octenidine Dihydrochloride onAntibiotics (Basel, Switzerland) · 2023Article
- Exploration of Baicalein-Core Derivatives as Potent Antifungal Agents: SAR and Mechanism Insights.Molecules (Basel, Switzerland) · 2023Article
- Qualitative metabolomics-based characterization of a phenolic UDP-xylosyltransferase with a broad substrate spectrum fromProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Therapeutic mechanism of baicalein in peritoneal dialysis-associated peritoneal fibrosis based on network pharmacology and experimental validation.Frontiers in pharmacology · 2023Article
- ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cellsFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baicalein (BE) is a promising antifungal small-molecule compound with an extended antifungal spectrum, good synergy with fluconazole, and low toxicity, but its target protein and antifungal mechanism remain elusive. In this study, we found that BE can function against Candida albicans by disrupting glycolysis through targeting Eno1 and inhibiting its function. Eno1 acts as a key therapeutic target of the drug, as BE had no antifungal activity against the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.